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Abstract
Study Objective—Previous studies suggest a risk of gastrointestinal events in patients prescribed
oral corticosteroids, but gastrointestinal events have not commonly been documented in patients
prescribed inhaled corticosteroids. We explored whether patients prescribed inhaled corticosteroids
are at risk of adverse gastrointestinal effects.
Design—A retrospective cohort study was conducted using 25 years of electronic medical record
data.
Setting—An urban health center with an academic affiliation.
Patients—The incidence of adverse gastrointestinal events in patients prescribed inhaled
corticosteroids and albuterol (n = 7,156) was compared to those prescribed albuterol alone (n =
12,287).
Measurements and Main Results—Adverse gastrointestinal outcomes included events such as
gastritis, ulcers, and bleeding. Cox proportional hazards models were used to determine the risk of
adverse events controlling for possible confounders such as alcohol use or non-steroidal anti-
inflammatory drug use. Adverse gastrointestinal events were observed in 461 (6.4%) patients
prescribed inhaled corticosteroids and albuterol and in 302 (2.5%) patients prescribed only albuterol.
Patients prescribed inhaled albuterol and inhaled corticosteroids had an increased risk of adverse
gastrointestinal events compared to patients prescribed only albuterol [hazard ratio 1.26 (95%
confidence interval 1.02 to 1.56)] after controlling for potential confounders. A prescription for a
spacer device reduced this risk among patients prescribed inhaled steroid [hazard ratio 0.26 (95%
confidence interval 0.20 to 0.34)].
Conclusions—Patients prescribed inhaled corticosteroids appear to have a slight risk of adverse
gastrointestinal events that is mitigated in patients prescribed a spacer device.
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Inhaled corticosteroids are commonly used to treat obstructive airways diseases including
asthma and chronic obstructive pulmonary disease (COPD). For asthma, inhaled
corticosteroids are the primary treatment of underlying airway inflammation and have been
shown to reduce morbidity, mortality, and the costs of health care.1-5 Inhaled corticosteroids
also are used in treating patients with COPD, although the benefits are less well confirmed.
6-8 For both asthma and COPD, inhaled corticosteroids are preferred over oral corticosteroids
for long-term treatment because of their high levels of topical anti-inflammatory activity and
low levels of systemic activity.9, 10 While inhaled corticosteroids are relatively safe and
effective, adverse effects may occur in patients receiving chronic treatment. Documented
adverse effects include adrenal suppression,11-13 osteoporosis in adults14, 15 or reduced
growth rates in children,16 cataracts,17-20 glaucoma,21, 22 and dermal thinning.23-25
Although evidence is conflicting, gastrointestinal complications such as ulcers and bleeding
may occur in patients treated with chronic oral corticosteroids. For example, a pooled analysis
of 71 controlled trials revealed a risk of gastrointestinal events with oral corticosteroids.26
Similarly, a case-control study of Medicaid data found an increased risk of gastrointestinal
events with corticosteroids, but also found that it was primarily restricted to patients treated
with non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids concomitantly.27
An analysis of the United Kingdom General Practice Research Database confirmed the
additional risk associated with concomitant NSAID administration, although this study also
found monotherapy with oral corticosteroids to pose significant risk of gastrointestinal adverse
events.28
Although evidence is somewhat contradictory, oral corticosteroids appear to have some degree
of heightened risk for adverse gastrointestinal events. Prior evidence suggests that inhaled
corticosteroids are not associated with gastrointestinal adverse events,29, 30 even though
studies have indicated that inhaled corticosteroids produce systemic effects, and there is some
degree of gastric exposure with inhaled products.11-25 We conducted an exploratory analysis
to ascertain whether inhaled corticosteroids are associated with gastrointestinal adverse events.
METHODS
Patients
Patients received their care and medications from Wishard Health Services, Indianapolis,
Indiana between 1977 and 2002. During this time, we identified adult patients (≥ 18 years of
age) with airways disease defined as a diagnosis of asthma or COPD prescribed an inhaled
sympathomimetic (i.e., albuterol). We required that patients had at least one clinic encounter
6 months before their first prescription for an inhaled steroid or albuterol. We excluded patients
with any evidence contained in their automated medical records of an adverse gastrointestinal
event (e.g., gastritis, gastrointestinal bleed, ulcer, and esophagitis) during the 6 months prior
to initiation of an inhaled steroid or albuterol. The study was approved by the Indiana University
- Purdue University Institutional Review Board.
Data Source
We used automated data from Regenstrief Medical Record System (RMRS). Beginning in
1974, the RMRS has been the central repository for clinical data for outpatients and inpatients
seeking care at Wishard Health Services, an inner-city medical center in Indianapolis, Indiana,
USA. The RMRS is a modular system containing registration and appointment data,
prescriptions (including over-the-counter products filled through a Wishard Pharmacy), and
diagnostic data from laboratory, radiology, and endoscopic procedures. Prescription data
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derive from two sources. The first source is an archival database spanning back to 1974
containing the drug dispensed and the dispensing date. The second source is a prescription
module spanning to 1992 created directly from the electronic prescription records containing
virtually all data on each drug dispensed including the physician’s instructions for use. In this
database, physicians’ orders for spacer devices were stored the same as all other prescriptions.
These modules capture both prescription and over-the-counter products, as long as they were
provided by the Wishard Health System. During the past decade, two internal surveys of adult
outpatients with uncomplicated hypertension, coronary artery disease, heart failure, and
obstructive airways disease indicated that patients seen at Wishard receive >95% of their
prescription and over-the-counter drugs at Wishard Health System pharmacies.31 Radiologic
and endoscopic data include the procedural dates and diagnoses of upper gastrointestinal
radiological examination and endoscopy.
Study Design
A retrospective cohort study design was used (Figure 1). Two groups were formed to represent
patients treated with an inhaled corticosteroid and a comparison group not prescribed an inhaled
corticosteroid. All study patients were required to have at least one sympathomimetic
prescription for the β2-adrenergic agonist albuterol. Patients in the inhaled steroid group were
those prescribed both inhaled corticosteroids and albuterol and patients in the albuterol
group were prescribed inhaled albuterol only. Because nasally administered corticosteroids
ultimately reach the stomach and duodenum, we also considered their use.
The index date for patients in the steroid cohort was the date of the patient’s first prescription
for one of the following inhaled corticosteroids: beclomethasone, flunisolide, fluticasone, or
triamcinolone. The index date for patients in the albuterol group was the date of the patient’s
first prescription for albuterol. The inhaled steroids budesonide and mometasone were not on
the Health System’s formulary during the time of this study, and thus were not included in our
analysis.
Main Outcome Measures
The primary endpoint was incident gastrointestinal ulcer, perforation, or bleeding as diagnosed
by a physician or identified by diagnostic procedure (radiology, endoscopy, sigmoidoscopy,
or colonoscopy). Qualifying diagnoses on patients’ problem lists included any gastrointestinal
ulceration, perforation, esophagitis, gastritis, hemorrhage, hematemesis, hematochezia, or
melena. We searched for evidence of patients reaching the endpoint after their index date but
before their last prescription for inhaled steroid in the inhaled steroid group or inhaled albuterol
in the albuterol group. For this analysis, we used prescription and endpoint data for the period
November 14, 1977 to February 19, 2002.
Statistical Methods
We followed patients from the index prescription date to endpoint or censoring. Patients
reaching the endpoint were considered as having experienced an adverse gastrointestinal event;
otherwise, follow-up was censored one month after their last prescription for inhaled steroid
or albuterol. Observations also were censored with death or when no additional observations
were recorded in the RMRS. The outcome represented the duration from the index prescription
to endpoint or censoring. The distribution of duration from the index date to the event (or
censoring) time was quantified by a survival function for each treatment group. Kaplan-Meier
curves were used to depict the estimated survival functions of patients in the inhaled steroid
and albuterol groups. The method also was used to illustrate the difference in survival
experience between inhaled steroid users with or without spacer devices. We conducted
subgroup analyses for patients without any evidence of prescriptions for NSAIDs because of
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previous work suggesting that concomitant NSAID use significantly increases risk with oral
steroids.27, 28
Cox proportional-hazards regression models were used to examine the association between
inhaled corticosteroids use and the development of the adverse gastrointestinal endpoint while
controlling for confounders and effect modifiers. These variables included baseline
demographics (age, race, sex) and relevant behavioral characteristics (smoking and alcohol
use), and comorbidities that could represent diagnostic biases (evidence of oral thrush or
gastroesophageal reflux disease). We also assessed the impact of short-term administration of
effect modifying medications that are known to have acute gastrointestinal effects administered
within six months prior to endpoint or censoring (e.g., acute administrations of oral
corticosteroids, iron containing medications, NSAIDs, theophylline, and alendronate). We
considered other potential effect modifying medications such as risedronate and etidronate,
but these drugs were not on formulary at the time of this study. Cox regression models were
created to adjust for the main effects (e.g., oral corticosteroids) and interactions such as
treatment by NSAIDs, smoking by alcohol use, gender by iron medication use. The final model
selected was based on the significance of the model predictors. The adjusted effect of the
inhaled corticosteroids was then tested using the Wald Chi-square test and the magnitudes of
effects quantified by the hazard ratios of the covariates and their confidence intervals.
Data from the prescription module of the RMRS from 1992 to 2001 were used to examine the
dose effect (as low, moderate, and high dose) of inhaled and nasal steroid. The definition of
low, moderate, and high dose was that used by the National Asthma Education and Prevention
Program Expert Panel Report.10 Patients receiving low dose inhaled steroid AND nasal steroid
were elevated to the moderate dose level and those receiving moderate dose inhaled steroid
AND nasal steroid were elevated to the high dose level.
A priori we wished to determine the effect of a spacer device on any observed risk of adverse
gastrointestinal events. As such, we conducted additional analyses to gain insights into the
effect of spacer use. We evaluated the effect of a prescription for a spacer on the development
of adverse gastrointestinal events in all study patients and then restricted our analysis to the
inhaled corticosteroid group. Analyses were conducted using SAS version 8.2 (SAS Institute,
Inc., Cary, NC, USA). Two-sided P values of less than 0.05 were used in statistical inferences.
RESULTS
Patient Characteristics
Of 28,272 patients prescribed an inhaled steroid or albuterol, 8,829 patients were excluded
because of a prior history of one of the endpoint diagnoses before their index prescription date.
Of the remaining 19,443 patients, there were 7,156 patients who had been prescribed both an
inhaled steroid and albuterol and 12,287 patients prescribed albuterol only. Beclomethasone
(59.5%) was the most commonly prescribed inhaled steroid followed by fluticasone (24.6%),
triamcinolone (13.9%), and flunisolide (2.1%). Among the inhaled steroid group, 5,695
(79.6%) used only an orally inhaled product and 1,461 (20.4%) used both orally and nasally
inhaled products. Patient characteristics of the inhaled steroid and albuterol study groups are
shown in Table 1. Patients in the inhaled steroid group were more likely older, a female, a
smoker, diagnosed with gastroesophageal reflux disease, and a recipient of NSAIDs, oral
corticosteroids, and a spacer device (p<0.0001). The mean (SD) duration of follow-up was 5.7
year (3.7), the median was 4.8 years, and the range was 1 to 24.3 years.
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Incident Adverse Gastrointestinal Events
Incident adverse gastrointestinal were observed in 763 (3.9 percent) of the 19,443 study patients
during the course of observation. Of the 7,156 patients in the inhaled steroid group, 461 (6.4
percent) experienced an event while receiving an inhaled steroid. The most common events
documented in the inhaled steroid group were gastritis (N = 163; 2.3 percent), gastrointestinal
bleed (N = 152; 2.1 percent), ulcer (N = 101; 1.4 percent), and esophagitis (N=45; 0.6%). Of
the 12,287 patients in the albuterol group, 302 patients (2.5 percent) experienced an adverse
gastrointestinal event, including: gastritis (N = 91; 0.7 percent), gastrointestinal bleed (N =
121; 1.0% percent), ulcer (N = 64; 0.5 percent), and esophagitis (N=26; 0.2%). The proportion
of patients experiencing a gastrointestinal event was greater in the inhaled steroid group than
the albuterol group, regardless of event type (P<0.05 for all).
Crude survival function estimates using Kaplan-Meier curves (Figure 2) show the change in
hazard function for all patients (Panel A) and the probability for patients who had not received
an NSAID (Panel B). Regardless of NSAID use, patients in the inhaled steroid group
experienced a greater risk of a gastrointestinal disorder than patients in the albuterol group
suggesting an association between the use of inhaled steroid and an incident gastrointestinal
disorder. However, such graphical representations do not control for other confounders.
Cox regression models further confirmed the finding after controlling for other risk factors and
covariates (Table 2). Patients in the inhaled steroid group had a greater risk of adverse
gastrointestinal events despite their NSAID status. For all patients, the risk (i.e., hazard ratio)
of adverse gastrointestinal event was 1.27 (95 percent confidence interval, 1.09 to 1.48),
whereas for those without evidence of NSAID use the risk was 1.26 (95 percent confidence
interval, 1.02 to 1.56). In other words, the risk of a gastrointestinal disorder was approximately
26% greater among patients prescribed an inhaled steroid and albuterol compared to patients
prescribed albuterol only. Other significant factors associated with the endpoint included older
age (P<0.001, hazard ratio=1.02), asthma (P=0.004, hazard ratio 0.74), cigarette smoking
(P<0.001, hazard ratio=1.40), alcohol use (P<0.001, hazard ratio=1.60), and the use of iron
containing medication (P=0.001, hazard ratio=1.55), NSAIDs (P<0.001, hazard ratio=1.31) or
theophylline (P<0.001, hazard ratio=1.43). Interestingly, the use of oral steroids was not
significant. We repeated our analyses excluding patients prescribed oral corticosteroids and
the inhaled steroid effect remained significant (data not shown, P=0.02). Moreover, in the
subset of patients prescribed inhaled corticosteroid between 1992 to 2001 (when more detailed
data on drug dispensing and directions for use were available), we found that the risk of adverse
gastrointestinal event was 3.7% among patients prescribed relatively low doses of inhaled
steroid, 4.5% among those prescribed moderate doses, and 8.8% among patients prescribed
high doses (P=0.03 for trend).
Effect of Receipt of a Spacer Device
Among all patients, receipt of a spacer (Table 2) had a significant mitigating effect on the risk
of adverse gastrointestinal events (P<0.001, hazard ratio=0.34). These results imply that the
risk of developing the adverse gastrointestinal events among patients prescribed a spacer was
66% lower than patients whom had not received a spacer.
To assess whether receipt of a spacer reduced the risk of adverse gastrointestinal event rates
specifically within the inhaled corticosteroid-treated patients, we compared the Kaplan-Meier
estimates of the hazard function of inhaled corticosteroid patients who had been prescribed a
spacer with that of patients who had not (Figure 3, Panels A and B). The evidence from Figure
2 suggests that receipt of a spacer device is indeed associated with a reduced risk of an adverse
gastrointestinal event. Cox regression models further confirmed this observation (Table 3).
The hazard ratio for receipt of a spacer was 0.29 (95 percent confidence interval, 0.24 to 0.35)
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among all patients prescribed inhaled corticosteroids and 0.26 (95 percent confidence interval,
0.20 to 0.34) among the subset of patients who had not been prescribed an NSAID. The results
imply that the risk of adverse gastrointestinal event is 71% less among patients who receive a
spacer device compared to those who do not.
DISCUSSION
Our results suggest that patients prescribed inhaled corticosteroids have a slight risk of adverse
gastrointestinal events (primarily gastritis), which is mitigated when patients receive a spacer
device. Oral corticosteroids have been implicated as a risk factor for adverse gastrointestinal
events such as ulcers for many years, but the current study is the first suggesting a possible
effect from inhaled corticosteroids.
While the target of inhaled drug is the lung, a considerable amount of inhaled corticosteroid
appears in the gastrointestinal tract including the lining of the esophagus, the stomach, intestine,
and colon.32, 33 Scintillation studies have revealed large boluses of radiolabeled drug
appearing in the stomach when metered dose inhalers are used without spacer devices.34
However, little drug is observed when the spacer device is used with the metered dose inhaler.
Presumably, the reduced amount of inhaled steroid that is swallowed or deposited in the
oropharynx and ultimately swallowed reduces the risk of adverse gastrointestinal events such
as gastritis, ulceration, and bleeding.
Our findings should be viewed in light of the conflicting evidence from previous studies
assessing risk with oral corticosteroids. Although a large meta-analysis26 indicated a risk of
ulceration from oral corticosteroids, this evidence is contradicted by a case control study27
that concluded the increased risk of developing peptic ulcer disease was limited to patients
with concurrent NSAID use. In our study, despite NSAID use, we found that patients treated
with oral steroids were not at a statistically significant higher risk of developing gastrointestinal
adverse events. However, inhaled corticosteroid-treated patients had a greater risk of
gastrointestinal adverse events even after controlling for NSAID use. A possible explanation
for the association of inhaled but not oral corticosteroids with gastrointestinal adverse events
may be related to the intensity or duration of exposure. The average duration of inhaled
corticosteroid exposure was roughly 1 year, while oral steroid use generally covered a shorter
time intervals (e.g., median duration = 1 month). Thus, part of the reason we identified a risk
of gastrointestinal adverse events with inhaled but not oral corticosteroids could be related to
differences in exposure. We measured both acute bursts and regular use for oral steroids, while
inhaled steroids were typically administered on a regular basis over longer periods of time.
This distinction likely biased our estimate of risk downward for oral steroids. More research
is needed to examine how long-term oral steroid use compares to long-term inhaled steroid
use.
We acknowledge several important limitations of this study. First, we used automated
observational data from a large health care system over a long duration assuming that drug use
during the interval between first and last prescription represented continuous use of drug. Such
practice data may have been collected differently over time, important changes may have
occurred with diagnostic instrumentation and procedures, and inhaled corticosteroids have
become increasingly potent. These factors could bias our findings. Second, although we were
able to account for patient level variables like smoking, alcohol use, and over-the-counter drug
use - variables often missed in observational studies such as ours - residual confounding could
exist and could possibly explain the small associations found. Third, comparison of an albuterol
group to an albuterol plus inhaled steroid group could be biased by severity or type of disease
(asthma versus COPD). Most of our sample included patients with a diagnosis of asthma and
we controlled for this in our analyses. Patients with COPD were at higher risk for
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gastrointestinal events than patients with asthma, which could be related to COPD patient’s
greater numbers of comorbidities and incidence of hospitalization. Fourth, we chose not to
match the index date of the albuterol cohort to the index date of the albuterol plus inhaled
steroid cohort because of the extent to which this would limit our sample size. However, this
decision could introduce a time bias that potentially could bias our hazard ratio upward. Fifth,
our endpoint was a diagnosis made by a physician using a variety of means including clinical
acumen or diagnostic procedures such as endoscopy. Our study results would have been more
compelling were we to use only endoscopic results. However, such procedural data were
available on a limited number of patients whom are not likely generalizable to our overall
patient population prescribed inhaled pharmacotherapy for airway disease. Sixth, we did not
adjust our analysis for use of antacids or gastro-protective drugs because of the sporadic use
of these drugs, and primarily with the drugs available during the early years of observation
(e.g., liquid antacids and histamine antagonists). Future studies should consider this important
confounder. Finally, our earlier archived data only accurately and consistently reflect
prescription date and drug but not dosage, which was the reasoning for using more recent data
to explore dose-effect. To some extent our design accounted for the length of drug exposure
by censoring observations at the time the drug no longer appeared in the records, but we were
unable to control for adherence. We are also limited in our understanding of the relationship
between drug potency, device, and variability in administration technique - factors that could
affect drug absorption in the gastrointestinal tract.33, 35 While our study did not include dry
powder delivery devices, market shift towards such formulations warrants further study of the
effect of delivery device. Our indicator of spacer use is based on whether a patient received
one, not whether the spacer was used properly or at all.
We conclude that patients prescribed inhaled corticosteroids may have a risk of adverse
gastrointestinal events that is mitigated with the use of spacer devices. Although the incidence
of such events is low (approximately 6%), these results provide further support for the use of
spacer devices with inhaled corticosteroids. Although we cannot determine whether patients
using dry powder devices are at increased risk for gastrointestinal events, our findings have
potential implications for these newer devices since spacers cannot be used. Additional
research should focus on dry powder delivery devices to determine whether recommendations
might be strengthened in this area.
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Figure 1. Study Design
COPD - chronic obstructive pulmonary disease; GERD - gastroesophageal reflux disease; GI
- gastrointestinal; SD - standard deviation
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Figure 2. Kaplan-Meier Estimates of the Percentage of Patients in Corticosteroid and Albuterol
Only (Sympathomimetics) Groups
Panel (A) All Patients, Panel (B) Patients who had not used NSAIDs within six months of the
event or censoring date; NSAID - Non-steroidal anti-inflammatory drug
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Figure 3. Kaplan-Meier Estimates of the Percentage of Patients Prescribed Inhaled corticosteroids
(With or Without Spacer)
Panel (A) All inhaled corticosteroids users, Panel (B) Inhaled corticosteroid users who had not
used NSAIDs within six months of the event or censoring date; NSAID - Non-steroidal anti-
inflammatory drug
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Table 1
Clinical Characteristics of the Study Sample
Variable Inhaled Corticosteroid &Albuterol (N = 7,156)
Albuterol Only (N =
12,287) Total (N = 19,443)
Age, mean (SD), y at index 34.0 (18.0) 30.5 (18.6) 31.8 (18.5)
Women, No. (%) 4,709 (65.8) 7,151 (58.2) 11,860 (61.0)
Black race, No. (%) 3,714 (51.9) 6,303 (51.3) 10,017 (51.5)
Asthma, No. (%) 6,083 (85.0) 11,181 (91.0) 17,264 (88.8)
COPD 1,073 (15.0) 1,106 (9.0) 2,179 (11.2)
Cigarette smoking, No. (%) 1,169 (16.3) 1,119 (9.1) 2,288 (11.8)
Alcohol use, No. (%) 973 (13.6) 1,769 (14.4) 2,742 (14.1)
Oral thrusha, No. (%) 14 (0.2) 12 (0.1) 26 (0.1)
GERDa, No. (%) 651 (9.1) 369 (3.0) 1,020 (5.2)
Iron medicationsa, No. (%) 372 (5.2) 700 (5.7) 1,072 (5.5)
NSAIDsa, No. (%) 2,476 (34.6) 3,576 (29.1) 6,052 (31.1)
Potassium supplements, No. (%) 964 (13.5) 750 (6.1) 1,714 (8.8)
Oral Steroida, No. (%) 1,553 (21.7) 1,290 (10.5) 2,843 (14.6)
Spacer devicea, No. (%) 5,331 (74.5) 7,077 (57.6) 12,408 (63.8)
Theophyllinea, No. (%) 444 (6.2) 491 (4.0) 935 (4.8)
Alendronatea, No. (%) 7 (0.1) 12 (0.1) 19 (0.1)
SD = standard deviation
COPD = chronic obstructive pulmonary disease
GERD = gastroesophageal reflux disease
NSAID = non-steroidal anti-inflammatory drug
a
Recorded after the index date but within 6 months of the event or censoring date.
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Table 2
Results of Multivariable Cox Regression Models Examining the Relationship between Inhaled Corticosteroid
Use and the Risk of Adverse Gastrointestinal Events
All patients (N=19,442) Patients who were not prescribed NSAIDS
within 6 months before the event or censoring
time (N = 13,393)
Variables in the model Hazard Ratio (95%
CI)
P-Value Hazard Ratio (95%
CI)
P-Value)
Inhaled corticosteroids (yes=1) 1.27 (1.09-1.48) 0.002 1.26 (1.02-1.56) 0.03
Sex (male=1) 0.98 (0.84-1.15) 0.81 0.90 (0.72-1.12) 0.33
Race (black=1) 0.80 (0.69-0.93) 0.003 0.84 (0.69-1.03) 0.09
Age (years, on the index date) 1.02 (1.02-1.03) <0.001 1.02 (1.01-1.02) <0.001
Asthma (yes=1) 0.74 (0.59-0.91) 0.004 0.68 (0.51-0.90) 0.006
Smoking (yes=1) 1.40 (1.19-1.65) <0.001 1.40 (1.10-1.77) 0.01
Alcohol use (yes=1) 1.60 (1.36-1.89) <0.001 1.86 (1.48-2.34) <0.001
Oral thrush a(yes=1) 2.45 (0.78-7.66) 0.13 1.68 (0.23-12.11) 0.61
GERD a(yes=1) 1.07 (0.86-1.32) 0.56 1.28 (0.95-1.71) 0.10
Iron-medications a(yes=1) 1.55 (1.19-2.01) 0.001 1.45 (0.98-2.14) 0.07
NSAIDs a(yes=1) 1.31 (1.13-1.51) <0.001 - -
Potassium supplements (yes=1) 1.27 (1.06 - 1.52) 0.008 1.16 (0.98-1.52) 0.27
Oral steroid a(yes=1) 1.09 (0.90-1.32) 0.36 1.09 (0.84-1.40) 0.52
Spacer a(yes=1) 0.34 (0.30-0.40) <0.001 0.34 (0.28-0.42) <0.001
Theophylline a(yes=1) 1.43 (1.16-1.75) <0.001 1.79 (1.36-2.34) <0.001
NSAID = non-steroidal anti-inflammatory drug
CI = confidence interval
GERD = gastroesophageal reflux disease
a
Referring to the time period after the index date but within 6 months of the event or censored date. One patient was removed from the analyses because
of a missing response.
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Table 3
Results of Multivariable Cox Regression Models Examining the Relationship between Spacer Use and the Risk
of Adverse Gastrointestinal Events in Patients Prescribed Inhaled Corticosteroids
All patients using inhaled corticosteroids
(N = 7,155)
Patients using inhaled corticosteroids but were
not prescribed NSAIDs within 6 months of the
event or censoring date (N = 4,679)
Variables in the model Hazard Ratio (95%CI) P Value
Hazard Ratio (95%
CI) P Value
Spacer (yes=1) 0.29 (0.24-0.35) <0.001 0.26 (0.20-0.34) <0.001
Sex (male=1) 1.03 (0.84-1.27) 0.77 0.92 (0.69-1.23) 0.59
Race (black=1) 0.84 (0.69-1.01) 0.06 0.86 (0.66-1.12) 0.26
Age on index date (years) 1.02 (1.01-1.02) <0.001 1.01 (1.01-1.02) 0.002
Asthma (yes=1) 0.76 (0.59-0.99) 0.044 0.64 (0.45-0.90) 0.01
Smoking (yes=1) 1.44 (1.17-1.77) <0.001 1.45 (1.08-1.95) 0.01
Alcohol use (yes=1) 1.53 (1.23-1.91) <0.001 1.80 (1.33-2.44) <0.001
Iron-medications *(yes=1) 1.62 (1.15-2.28) 0.006 1.67 (1.02-2.71) 0.04
NSAIDs *(yes=1) 1.35 (1.12-1.62) 0.002 - -
Potassium supplements (yes=1) 1.37 (1.10-1.72) 0.006 1.36 (0.98-1.90) 0.06
Oral steroid *(yes=1) 1.24 (0.99-1.54) 0.06 1.23 (0.92-1.65) 0.16
Theophylline *(yes=1) 1.47 (1.15-1.88) 0.002 1.80 (1.30-2.49) <0.001
NSAID = non-steroidal anti-inflammatory drug
CI = confidence interval
*
Referring to the time period after index date but within 6 months of the event or censoring date. One patient was removed from the analyses because of
a missing response.
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